Kasper S, Beckmann H
Acta Psychiatr Scand. 1983 Jul;68(1):31-7. doi: 10.1111/j.1600-0447.1983.tb06978.x.
Using a pluridiagnostic approach, the dexamethasone suppression test (DST) was studied in 67 depressed inpatients in its relationship to diverse clinical variables. The International Classification of Diseases (ICD), the Research Diagnostic Criteria (RDC), the Newcastle Index, the Hamilton Depression Rating scale (HAM-D), and the Bf-s self rating questionnaire were applied. Fifty-two per cent of endogenous depressed (ICD), 51% of major depressive (RDC) and 53% of endogenous depressed (Newcastle) patients demonstrated dexamethasone nonsuppression (DSTN) with a value above 110 nm/l. Six per cent of neurotic depressed (ICD), 9% of minor depressive (RDC) and 23% of neurotic depressed (Newcastle) patients were dexamethasone nonsuppressors. Significantly higher values (after P-correction) for DSTN could be detected in severity ratings as measured with Newcastle (P less than 0.001) and HAM-D global score (P less than 0.001) and also for HAM-D factor 4 (somatic complaints, P = 0.001). All the other evaluated variables did not discriminate between patients with dexamethasone suppression and with nonsuppression.
采用多诊断方法，对67例住院抑郁症患者的地塞米松抑制试验（DST）与多种临床变量的关系进行了研究。应用了国际疾病分类（ICD）、研究诊断标准（RDC）、纽卡斯尔指数、汉密尔顿抑郁量表（HAM-D）和Bf-s自评问卷。52%的内源性抑郁症患者（ICD）、51%的重度抑郁症患者（RDC）和53%的内源性抑郁症患者（纽卡斯尔）表现出地塞米松不抑制（DSTN），值高于110 nmol/l。6%的神经症性抑郁症患者（ICD）、9%的轻度抑郁症患者（RDC）和23%的神经症性抑郁症患者（纽卡斯尔）为地塞米松不抑制者。在用纽卡斯尔量表（P<0.001）和HAM-D总分（P<0.001）以及HAM-D因子4（躯体主诉，P = 0.001）测量的严重程度评分中，可以检测到DSTN的显著更高值（经P校正后）。所有其他评估变量在有地塞米松抑制和无抑制的患者之间没有差异。
